Camonsertib

DRUG5 trials

Sponsors

F. Hoffmann-La Roche AG, Hoffmann-La Roche, National Cancer Institute (NCI)

Conditions

Carcinoma, Non-Small-Cell LungClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic non-small cell lung cancer (NSCLC)Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma

Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

CompletedNCT03337698

Hoffmann-La RocheCarcinoma, Non-Small-Cell Lung

Start: 2017-12-27End: 2025-11-25Updated: 2025-12-12

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

CompletedCTIS2023-504038-23-00

F. Hoffmann-La Roche AGMetastatic non-small cell lung cancer (NSCLC)

Start: 2018-05-10End: 2025-04-02Target: 149Updated: 2025-02-14

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Not yet recruitingNCT07156227

National Cancer Institute (NCI)Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma +27

Start: 2026-06-22End: 2029-05-31Target: 39Updated: 2026-04-03

Phase 2

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Active, not recruitingNCT04589845

Hoffmann-La RocheSolid Tumors

Start: 2021-01-18End: 2032-09-25Target: 920Updated: 2026-04-02

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruitingCTIS2023-507418-28-00

F. Hoffmann-La Roche AGSolid tumors

Start: 2021-03-15Target: 407Updated: 2025-12-09

Related Papers

Abstract 1047: MORPHEUS-lung: Biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer

Cancer Research2026-04-03

Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Data from the TAPISTRY trial.

Journal of Clinical Oncology2026-01-10

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

2026-01-09

Updated efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>ROS1</i> fusions.

Journal of Clinical Oncology2025-05-28

Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial

Cancer2025-05-141 citations

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.

2025-04-075 citations

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

European Journal of Cancer2025-02-224 citations

TRLS-12. EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITH<i>NTRK</i> OR<i>ROS1</i> FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

Neuro-Oncology2024-06-18

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Journal of Clinical Oncology2024-06-051 citations

Ipatasertib in patients with <i>AKT1/2/3</i> mutation-positive (<i>AKT</i>mut) tumors: TAPISTRY study.

Journal of Clinical Oncology2024-06-014 citations

Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>NTRK</i> or <i>ROS1</i> fusions.

Journal of Clinical Oncology2024-06-012 citations

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

JNCI Journal of the National Cancer Institute2024-05-069 citations

Abstract CT265: Trastuzumab emtansine in patients (pts) with <i>HER2</i> mutation-positive <i>(HER2</i>mut<i>)</i> tumors: TAPISTRY study

Cancer Research2024-04-05

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i>-fp) solid tumors.

Journal of Clinical Oncology2022-06-0130 citations

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

BMJ Open2022-05-0113 citations

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

ESMO Open2021-11-1910 citations

Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.

Journal of Clinical Oncology2021-05-2011 citations

Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

Chinese Medical Journal2020-09-15

Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Cancer Research2020-08-154 citations

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of Oncology2018-10-0119 citations

1 more papers not shown